Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives

• Published in: Advanced drug delivery reviews Vol. 214; p. 115447
• Main Authors: Mak, Wen Yao, He, Qingfeng, Yang, Wenyu, Xu, Nuo, Zheng, Aole, Chen, Min, Lin, Jiaying, Shi, Yufei, Xiang, Xiaoqiang, Zhu, Xiao
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.11.2024
• Subjects: Antibacterial; Antiviral; Host system dynamics; Immune system; MIDD; Pharmacodynamic; Pharmacokinetic; Resistance; Resistance; Host system dynamics; MIDD; Pharmacodynamic; Antiviral; Antibacterial; Pharmacokinetic; Immune system
• ISSN: 0169-409X; 1872-8294; 1872-8294
• DOI: 10.1016/j.addr.2024.115447

[Display omitted] This review examines the role of model-informed drug development (MIDD) in advancing antibacterial and antiviral drug development, with an emphasis on the inclusion of host system dynamics into modeling efforts. Amidst the growing challenges of multidrug resistance and diminishing market returns, innovative methodologies are crucial for continuous drug discovery and development. The MIDD approach, with its robust capacity to integrate diverse data types, offers a promising solution. In particular, the utilization of appropriate modeling and simulation techniques for better characterization and early assessment of drug resistance are discussed. The evolution of MIDD practices across different infectious disease fields is also summarized, and compared to advancements achieved in oncology. Moving forward, the application of MIDD should expand into host system dynamics as these considerations are critical for the development of “live drugs” (e.g. chimeric antigen receptor T cells or bacteriophages) to address issues like antibiotic resistance or latent viral infections.